Core administrative hub for a multifaceted cancer center program
Official title: Core 1: Administrative Core
Funded at Dana-Farber Cancer Inst · NIH-11644426 · Data updated 2026-11-12
A large, international cancer research program at Dana-Farber aims to advance a curative strategy for multiple myeloma by coordinating translational research, clinical trials, and data analysis.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | December 1, 2011 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $161,714 |
| NIH project number | 3P01CA155258-14S1 |
| Project ID | NIH-11644426 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with multiple myeloma undergoing autologous stem cell transplantation and contributing samples for genomic/epigenomic analyses.
✕Less likely to help
Patients not undergoing autologous stem cell transplantation or not contributing samples may not directly benefit.
What this research studies
This project brings together leaders from Dana-Farber, Harvard, MIT, and a French myeloma group to move toward cures for multiple myeloma. It focuses on how deep genomic and epigenomic information can guide treatment decisions after autologous stem cell transplant, with a goal of MRD-negative status and better survival. The core supports collaboration, study coordination, data sharing, and administrative planning to accelerate therapeutic advances. Researchers will analyze samples from patients who received high-dose melphalan and transplant to identify biomarkers and validate new targeted approaches.
Why it matters
Potential benefit: If successful, patients with multiple myeloma could receive more precise, effective treatments that improve long-term survival and chances of cure.
How similar studies have gone: Previous work confirmed MRD-negative status after high-dose melphalan and transplant, supporting further exploration of MRD-guided therapy strategies.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Munshi, Nikhil C. — Dana-Farber Cancer Inst
- Study coordinator: Munshi, Nikhil C.
Related research
Other NIH-funded projects on the same topics.
-
Helping young people with cancer understand their genetic risks
This study is creating a special program to help teenagers and young adults with hereditary cancer risks learn about their health and make smart choices, while also supporting their families along the way.
-
Automated, interactive lab tool to define radiation targets in cancer care
Aims to make it easier and safer to outline the area to treat in radiation therapy for cancers by using smart software and a patient-friendly interface.
-
Cancer Atlas Network data hub to share big cancer data
A national project helps researchers store, harmonize, and share large cancer data collections so doctors and scientists can learn from many patients.
-
Bridge-building cancer research partnership for education, outreach, and science
A joint effort between UMass Boston and Harvard Cancer Consortium to accelerate cancer research and education by connecting lower-resourced institutions with a leading cancer center.
-
NexTGen: Next-Generation T cell therapy for childhood cancers
A charity-friendly overview: researchers at Dana-Farber are developing advanced engineered T-cell therapies to treat pediatric solid cancers like brain tumors and sarcomas.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.